74041-5

BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular genetics method --post treatment

Active

Term Description

Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy. A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to control gene is less than or equal to 0.1% according to the International Scale (IS), a consensus standardized measurement scale intended to allow direct comparison of BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use. Studies have demonstrated that achieving MMR within 18 months following TKI therapy is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML, 2013).
Source: Regenstrief LOINC

Fully-Specified Name

Component: t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1%^post treatment
Property: PrThr
Time: Pt
System: Bld/Tiss
Scale: Ord
Method: Molgen

Additional Names

Short Name: t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql
Display Name: t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 fusion transcript/control transcript.reduction to 0.1% post treatment Molgen Ql (Bld/Tiss)
Consumer Name Alpha Get Info: t(9;22)(q34.1;q11)(ABL1,BCR) B2a2+b3a2/control Transcript.reduction to 0.1% - after Treatment, Blood or tissue specimen

Example Answer List: LL365-8

Source: HL7

Code System: HL7v2
Code System OID: 2.16.840.1.113883.12.136

Answer	Code	Score	Answer ID
YesCopyright http://snomed.info/sct ID:373066001 Yes (qualifier value)	Y		LA33-6
NoCopyright http://snomed.info/sct ID:373067005 No (qualifier value)	N		LA32-8

Basic Attributes

Class: MOLPATH
Type: Laboratory
First Released: Version 2.46
Last Updated: Version 2.56
Change Reason: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation: Both

Language Variants Get Info

Tag	Language	Translation
es-ES	Spanish (Spain)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 Tránscritos de fusión/control transcripción.reducción al 0,1%^Post tratamiento:PrThr:Punto temporal:Sangre o tejido:Ord:Genética molecular
es-MX	Spanish (Mexico)	t (9; 22) (q34.1; q11) (ABL1, BCR) transcripción de fusión b2a2 + b3a2 / transcripción de control reducción a 0.1%^ después del tratamiento:Presencia o umbral:Punto temporal:Sangre o tejido:Ordinal:Genética molecular
fr-FR	French (France)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcrit de fusion/transcrit de référence réduction à 0.1% après traitement:Présence/Seuil:Ponctuel:Sang/Tissu:Qualitatif:Biologie moléculaire
fr-CA	French (Canada)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcrit de fusion/Transcrit de contrôle. Réduction à 0,1%^post traitement:Présence-Seuil:Temps ponctuel:Sang/Tissu:Ordinal:Molgen
it-IT	Italian (Italy)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2, trascritto di fusione/Trascrizione di controllo.riduzione al 0.1%^post trattamento:PrThr:Pt:Sangue/Tess:Ord:Molgen Synonyms: dopo trattamento Genetica molecolare Patologia molecolare Presenza o Soglia Punto nel tempo (episodio) Sangue Sangue o Tessuto Tessuto & Strisci
pt-BR	Portuguese (Brazil)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 transcrição de fusão/controle de transcrição para 0.1%^pos tratamento:Limiar:Pt:Sg/Tecido:Ord:Genética molecular
ru-RU	Russian (Russian Federation)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 слияния транскрипт/контрольный транскрипт.редукция до 0.1%^после лечения:PrThr:ТчкВрм:Кр/Тк:Пор:МолГен Synonyms: Кровь Кровь или Ткань Порядковый Ткань и мазки Точка во времени;Момент химерная РНК, закодированная слитым геном
tr-TR	Turkish (Turkey)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 füzyon transkript/kontrol transkript.%0.1'e düşürme^tedavi snr:MevcEşik:Zmlı:Kan/Dk:Srl:Molgen Synonyms: Mevcut
zh-CN	Chinese (China)	t(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 融合转录物/对照转录物.降低至 0.1%^在治疗之后:存在情况或阈值:时间点:全血/组织:序数型:分子遗传学类实验室方法 Synonyms: ABL CML JTK7 p150 v-abl Abelson murine leukemia viral oncogene homolog 1 v-abl Abelson 小鼠白血病病毒癌基因同源体 1 v-abl Abelson 小鼠白血病病毒肿瘤基因同源体 1 v-abl Abelson 小鼠白血病病毒致癌基因同源体 1 v-abl Abelson 鼠科动物白血病病毒致癌基因同源体 1 v-abl Abelson 鼠科白血病病毒致癌基因同源体 1 XXX刺激 - 在...之后之后于... 之后于治疗;在处理之后依次型;分类顺序型;定性的;序数型（或称等级型）;性质上的;有序型;有序性分类应答;有序性分类结果;秩次型;等级型;筛查;顺序型全血或组织;血液/组织;血液或组织分子病理学;分子病理学试验分子遗传学;分子遗传学方法;分子遗传学类方法;分子遗传学类检验方法;包括 RFL、PCR 及其他方法在内，用于在分子基础上检测遗传属性的方法的大类;聚合酶链反应;聚合酶链式反应在...以后在后存在情况;存在;存在与否;是否存在;阈值;界值;界限;阀值;临界值;存在情况（存在、存在与否、是否存在）或阈值（界值、界限、阀值、临界值）慢性粒细胞性白血病慢性粒细胞白血病慢性粒细胞白血病（Chronic myeloid leukemia，CML）慢性髓系白血病断点簇集区断裂点丛集区断裂点簇集区断裂点聚集区断裂点集中区断裂点集中区（Breakpoint cluster region，BCR）时刻;随机;随意;瞬间易位(9;22)(q34.1;q11)(ABL1,BCR) 易位(9;22)(q34.1;q11)(ABL1,BCR) b2a2 易位(9;22)(q34.1;q11)(ABL1,BCR) b2a2+b3a2 未作说明的组织;组织;组织 & 涂片融合转录物（转录本、转录产物、转录子、转录）;融合基因转录本;融合转录血;血液限制性断裂区

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

CodeSystem lookup: https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=74041-5

Third Party Copyright

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.